• Publications
  • Influence
Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)
The Gynecological Cancer Intergroup (GCIG) has previously reached consensus regarding the criteria that should be used in clinical trial protocols to define progression-free survival after first-lineExpand
  • 370
  • 16
Molecular pathways regulating EGF-induced epithelio-mesenchymal transition in human ovarian surface epithelium.
The ovarian surface epithelium (OSE) is the precursor of common epithelial ovarian carcinomas. In the present study, we examined the molecular mechanisms and possible physiological basis for theExpand
  • 187
  • 15
Chapter 8: Screening for cervical cancer in developing countries.
Organised and quality assured cytology-based screening programmes have substantially reduced cervical cancer incidence in many developed countries. However, there are considerable barriers to settingExpand
  • 257
  • 15
  • PDF
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial
Summary Background Although women with endometrial cancer generally have a favourable prognosis, those with high-risk disease features are at increased risk of recurrence. The PORTEC-3 trial wasExpand
  • 186
  • 12
  • PDF
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
Summary Background The ICON7 trial previously reported improved progression-free survival in women with ovarian cancer with the addition of bevacizumab to standard chemotherapy, with the greatestExpand
  • 398
  • 11
  • PDF
Epidemiology and prevention of cervical cancer in Indonesia, Malaysia, the Philippines, Thailand and Vietnam.
Cervical cancer remains one of the leading causes of cancers in women from Indonesia, Malaysia, the Philippines, Thailand and Vietnam. High-risk human papillomavirus (HPV) types, particularly HPV-16Expand
  • 88
  • 11
Reproductive and other factors and risk of epithelial ovarian cancer: An australian case‐control study
Of the few factors known to be associated with epithelial ovarian cancer, the most consistently observed relate to women's reproductive function, although even here uncertainties remain. We haveExpand
  • 251
  • 9
Epithelial–mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: An exception to the norm
Cancer that arises from the ovarian surface epithelium (OSE) accounts for approximately 90% of human ovarian cancer, and is the fourth leading cause of cancer‐related deaths among women in developedExpand
  • 213
  • 9
Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell‐like profile
Epithelial mesenchymal transition (EMT) and cancer stem cells (CSC) have been associated with resistance to chemotherapy. Eighty percent of ovarian cancer patients initially respond to platinum‐basedExpand
  • 194
  • 9
The risk of preterm birth following treatment for precancerous changes in the cervix: a systematic review and meta‐analysis
Please cite this paper as: Bruinsma F, Quinn M. The risk of preterm birth following treatment for precancerous changes in the cervix: a systematic review and meta‐analysis. BJOG 2011;118:1031–1041.
  • 157
  • 8